Overview
- Authors:
-
-
James E. Talmadge
-
NCI-Frederick Cancer Research Facility, Frederick, USA
-
Isaiah J. Fidler
-
M.D. Anderson Hospital and Tumor Institute, Houston, USA
-
Robert K. Oldham
-
Biological Therapy Institute, Franklin, USA
Access this book
Other ways to access
Table of contents (4 chapters)
-
Front Matter
Pages i-xiii
-
- James E. Talmadge, Isaiah J. Fidler, Robert K. Oldham
Pages 1-14
-
- James E. Talmadge, Isaiah J. Fidler, Robert K. Oldham
Pages 15-119
-
- James E. Talmadge, Isaiah J. Fidler, Robert K. Oldham
Pages 121-178
-
- James E. Talmadge, Isaiah J. Fidler, Robert K. Oldham
Pages 179-193
About this book
The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search for new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for "screening" drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6).
Authors and Affiliations
-
NCI-Frederick Cancer Research Facility, Frederick, USA
James E. Talmadge
-
M.D. Anderson Hospital and Tumor Institute, Houston, USA
Isaiah J. Fidler
-
Biological Therapy Institute, Franklin, USA
Robert K. Oldham
